BMS in-licensed PKC theta inhibitor enters clinical trials
European Pharmaceutical Review
FEBRUARY 6, 2023
The compound is in development for immunology and inflammation indications. In May 2021, Bristol Myers Squibb and Exscientia expanded the collaboration in immunology & inflammation indications and oncology. The post BMS in-licensed PKC theta inhibitor enters clinical trials appeared first on European Pharmaceutical Review.
Let's personalize your content